Company news
Liquidia Corporation news in 2024
Liquidia Corporation's news releases, calls and decks from 2024, newest first.
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
Liquidia to Present at the Stifel 2024 Healthcare Conference
November 11, 2024
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
November 5, 2024
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
November 3, 2024
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
October 6, 2024
Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
October 1, 2024
Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
September 29, 2024
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
September 15, 2024
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
September 10, 2024
Liquidia to Present at Upcoming Investor Conferences
August 27, 2024
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
August 21, 2024
U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
August 18, 2024
Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
August 15, 2024
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 6, 2024
Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024
July 30, 2024
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
June 17, 2024
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
June 2, 2024
Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
May 28, 2024
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 12, 2024
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
May 9, 2024
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
May 6, 2024
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
May 6, 2024
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
April 1, 2024
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
March 31, 2024
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
March 12, 2024
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
March 5, 2024
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
January 29, 2024
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
January 24, 2024
Liquidia Corporation Announces Updates to Operations Leadership
January 18, 2024
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
January 7, 2024
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
January 4, 2024
Liquidia Corporation Announces $100 Million in New Financings
January 3, 2024
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 1, 2024